Movement Alert|BIOCYTOGEN-B Falls 5.26% in Regular Trading, CMB Group Cuts Stake to 7.91% After Three Consecutive Rounds of Selling

Market Focus09-24

On September 24, BIOCYTOGEN-B fell 5.26% in regular trading, trading at 66.55 HKD/share, with turnover of approximately HKD 82.72 million. The decline came after the company disclosed multiple stake change filings on September 23, revealing that China Merchants Bank, CMB International Financial, and affiliated entities sold 999,500 shares off-exchange on September 17 at an average price of HKD 59.6951 per share, totaling approximately HKD 59.67 million. The group's long position dropped from 8.81% to 7.91%.

Notably, this marks the third consecutive round of selling by the CMB-affiliated group since early September. The stake has been progressively reduced from 10.95% to 9.91% on September 1, then to 8.81% on September 8, and now to 7.91%, with cumulative disposals exceeding 3.36 million shares and total proceeds approaching HKD 200 million. The sustained selling signal has weighed on short-term market sentiment. Meanwhile, the broader Biotechnology sector showed broad-based weakness, with peers including INNOCARE down 10.48%, REMEGEN down 8.06%, AKESO down 3.64%, and INNOVENT BIO down 3.63%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment